About 2,561,255 results

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
JAMA Internal Medicine;

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

Expert Perspective on ASCO20 Quality Research

Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

COVID-19 in Immunocompromised Hosts: What We Know So Far
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients

Jun 1st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Add-On Selinexor Boosts PFS in Pretreated Myeloma

May 31st, 2020 - share to facebook share to twitter share to linkedin email article Including the XPO1 inhibitor selinexor (Xpovio) in a weekly bortezomib (Velcade) regimen improved oncologic outcomes and reduced rates of neuropathy in relapsed or refractory multiple myeloma, the phase III BOSTON trial showed.

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Prior chemotherapy linked to mortality risk among patients with thoracic cancers, COVID-19

May 29th, 2020 - Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death

May 29th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

ACA Medicaid Expansion Shows Cancer Survival Benefit, With Greatest Gains in Hispanic Populations

May 29th, 2020 - States that expanded access to Medicaid under the Affordable Care Act (ACA) in the United States showed a measured cancer survival benefit, and Hispanic patients experienced the greatest decline in mortality, according to a study (Abstract 2003) presented during the ASCO20 Virtual Scientific Program.

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma

May 29th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

Active Cancer Strongly Associated With Increased COVID-19 Mortality

May 28th, 2020 - An analysis of data collected in the COVID-19 and Cancer Consortium (CCC19) registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 (COVID-19) compared with patients in remission or with no evidence of disease.

Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer

May 28th, 2020 - Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.

COVID-19-Related Mortality Risk Increases With Recent Chemotherapy in Thoracic Cancer

May 28th, 2020 - The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a coronavirus disease 2019 (COVID-19) diagnosis, findings from the global TERAVOLT Consortium registry show.

COVID-19 Mortality Shows Strong Correlation With Active Cancer

May 28th, 2020 - Death in patients with progressive cancer within 30 days of the coronavirus disease 2019 (COVID-19) diagnosis was 5.2 times compared with patients in remission or with no evidence of disease, data from the COVID-19 and Cancer Consortium (CCC19) registry shows.

Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults
JAMA Oncology; Gilchrist SC

Jun 18th, 2020 - Is sedentary behavior as determined by accelerometry associated with future risk of cancer mortality in middle-aged and older US adults?

Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis
BMC Rheumatology;

Mar 5th, 2020 - Despite high risk for cardiovascular disease (CVD) mortality, screening and treatment of hyperlipidemia in patients with rheumatoid arthritis (RA) is suboptimal. We asked primary care physicians (PCPs) and rheumatologists to identify barriers to screening and treatment for hyperlipidemia among patients with RA.

Neurologic Features in Severe SARS-CoV-2 Infection

We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020.